YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Advanced Melanoma

Treatments: Drug: Ipilimumab

Study type: Observational

Funder types: Industry

Identifiers

NCT02224768

CA184-242

Details and patient eligibility

About

To evaluate the effectiveness of the YERVOY® educational Risk Minimization (RM) tools in terms of awareness about these tools, their utilization, knowledge and comprehension of Immune Related Adverse Reaction (irAR)s, and appropriate behavior by Healthcare Professional (HCP)s and patients

Full description

A total sample size of 160 to 200 HCPs and 160 to 200 patients

Enrollment: 158 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• HCP experienced in the treatment of patients with the research compound and patients that have received at least one dose

Trial design

158 participants in 1 patient group

HCP and Patient inclusion

Description:

HCP inclusion - HCP Experience with treatment of patients with study compound who have been exposed to risk minimization tools Patient inclusion - Patients treated with study compound as per label who have been exposed to the risk minimization materials

Treatment:

Drug: Ipilimumab